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Abstract
Background: The United States (US) Food & Drug Administration (FDA) recently approved a
human papillomavirus (HPV) vaccine with the purpose of reducing the risk of cervical cancers
caused by HPV 16 and HPV 18. It is important that the general population be educated about HPV
and the HPV vaccine in order to make the appropriate decision whether or not to vaccinate against
this virus. Participants from the adult US general population of Pittsburgh, Pennsylvania, USA and
Hampton, Virginia, USA (18+ years old) were surveyed to determine their knowledge about HPV
and the HPV vaccine, and to evaluate their perception of the vaccine efficacy and safety.
Results: We report herein preliminary data for 202 participants. Fifty-five percent (55%) of the
study population was White, 45% Black, and 1% was from other ethnic groups or did not disclose
their ethnicity. A large proportion of participants had heard of the human papillomavirus (overall
population: 93.6%; Pittsburgh: 95%; Hampton: 90%). Participants of African descent were slightly
less aware of HPV than Whites (Black 89% vs. Whites 97%, p > 0.1). Although the majority of
participants knew that HPV caused cervical cancer (84%), Whites were more informed than Black
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participants (91% vs. 73%, p = 0.044). Eighty-seven percent (87%) of participants had heard of the
HPV vaccine (Pittsburgh: 92% and Hampton: 74%, p = 0.029); a higher proportion of Whites were
aware of the vaccine when compared with Blacks (93% vs. 76%, p = 0.031). However, only 18% of
the population knew that the current FDA-approved vaccine protected against genital warts and
most cervical cancer (20% of Blacks and 16% of Whites, p > 0.1).
Conclusion: These data suggest that although the general population might be aware of HPV and
the HPV vaccine, knowledge of the benefits of the HPV vaccination may not be apparent.
Knowledge of HPV and the HPV vaccine could result in a likely choice of HPV vaccination and
would subsequently reduce the incidence of cervical cancer.
Background
Human papillomavirus (HPV) is a family of viruses that
are etiologically linked to number of disease conditions:
cancers as well as benign conditions such as warts and
condylomas. Although there are treatments for the clinical
manifestations of HPV infection, there is no cure for the
infection. There are at least 15 high-risk HPV types that
cause cervical cancer and most anogenital cancers; HPV
types 16 and 18 are the most common. In addition,
HPV16 is thought to be linked to the development of a
subset of head and neck cancers [1,2].
The United States (US) Food & Drug Administration
(FDA) recently approved an HPV vaccine with the pur-
pose of reducing the risk of cervical cancers caused by HPV
16 and HPV 18 [3]. The Centers for Disease Control and
Prevention (CDC) Advisory Committee on Immuniza-
tion Practices (ACIP) recommended routine HPV vaccina-
tion for 11–12 year olds and for girls as young as 9 years
old. The committee also recommended the vaccination of
13–26 year old females who have not been previously vac-
cinated or have not completed the full vaccination series
[4].
The HPV vaccine prevents infections from HPV types 6,
11, 16 and 18. HPV types 6 and 11 are primarily respon-
sible for the development of genital warts, while HPV
types 16 and 18 are attributed to the development of
approximately 70% of all cervical cancers [5,6]. The CDC
has made the HPV vaccine available through the Federal
Vaccines for Children (VFC) program in all 50 states [7].
Currently there are no federal laws that require children or
adolescents to be vaccinated. The only state that has man-
dated HPV vaccination of girls for school attendance is
Virginia. However, this state is currently considering a bill
that will delay that requirement [8]. Nevertheless, for
many states, HPV vaccination is voluntary. Therefore, it is
important that the general population be educated about
HPV and the HPV vaccine so that an informed decision
can be made as to whether or not to vaccinate against this
virus.
We have developed a survey that assesses the general pop-
ulation's knowledge and perception of HPV as well as the
HPV vaccination. This report summarizes data collected
from a sample of the general population residing in Pitts-
burgh, Pennsylvania, USA and Hampton, Virginia, USA.
We have compared the knowledge and attitudes between
the populations from these states.
Methods
Study population
The survey was administered to participants from the gen-
eral population of Pittsburgh, Pennsylvania and Hamp-
ton, Virginia, 18 years of age and older. Insitutional
Review board approval was obtained from both the Uni-
versity of Pittsburgh and Hampton University. The sur-
veys were distributed face-to-face or by mail. The
Pittsburgh population consisted of participants who were
enrolled in a population-based registry of people from
Pittsburgh and surrounding communities. These partici-
pants were recurited through flyers posted at churches,
community centers, outpatient clinics, health fairs, school
events, libraries, the local newspapers, and the University
of Pittsburgh Medical Center newsletters. A letter of invi-
tation to participate was mailed along with the question-
naire and interested participants completed and returned
the survey by mail. A total of 209 (192 Whites, 14 Blacks
and 2 from other ethnic groups) surveys were mailed and
103 participants (49.3%) responded (98 Whites, 2 Blacks,
one from another ethnic group and two who did not dis-
close their ethnicity). Additional participants (N = 23, 19
Blacks and 4 Whites) were recruited face-to-face, from an
ongoing study on participants who were at one time seen
as patients at the Magee Womens Hospital. The response
rate for the face-to-face recruitment was 23/60 (38%). The
Hampton population consisted of participants from
Hampton and surrounding communities, such as the
local plasma donation center, churches, the local police
station, and also students and staff members from the
Hampton University campus (68 Blacks, 7 Whites and
one from another ethnic group). These participants were
recruited face-to-face. All of the surveys for both study
populations were completed anonymously.Infectious Agents and Cancer 2009, 4(Suppl 1):S10 http://www.infectagentscancer.com/content/4/S1/S10
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Questionnaire
The questionnaire development was guided by our
research hypotheses and a review of the literature, and
consists of questions that define the participant's age, gen-
der, ethnicity, birthplace, marital status, parental status,
number of children, level of education, religion, health
insurance coverage and yearly household income. Partici-
pants were also asked to answer questions that would
evaluate their level of knowledge of HPV and the HPV vac-
cine. Questions related to the participant's perception of
the safety, efficacy and impact of HPV vaccination were
also included in the survey. A preliminary content asses-
ment of the survey was performed prior to the initiation
of this study.
Statistical analysis
All statistical analyses were performed using STATA SE
(version 10) software (StataCorp LP, College Station, TX,
USA). A two-sample proportions test of significance was
performed when comparing demographic variables and
the survey answers between stratified groups. Compari-
sons of continuous variables were performed using the
two-sample t-test. A p-value < 0.05 was considered statis-
tically significant. Adjusted prevalence rates for each sur-
vey answer were calculated for all participants and
stratified by ethnic groups and population source (Pitts-
burgh and Hampton) after adjusting for potential con-
founding variables, such as age, marital status, education,
income, recruitment location, and parental status. Com-
parisons of the number of correct answers for HPV knowl-
edge and HPV vaccine knowledge questions stratified by
race and recruitment location were calculated using two-
way ANOVA models after adjusting for age, marital status,
education, income, recruitment location and parental sta-
tus. Box plots were generated using the adjuste mean
vaules for each stratifed model.
Results
Description of the study populations
A total of 202 participants completed the survey (62%
from Pittsburgh and 38% from Hampton – Table 1). The
Hampton population consisted of younger individuals
compared with the Pittsburgh population (Hampton: 18–
35 = 87%, 36–55 = 11%, 56+ = 3% vs. Pittsburgh: 18–35
= 20%, 36–55 = 45%, 56+ = 35%). Overall, 54.5% of the
study population was White, 44.5% Black, and 1% was
from other ethnic groups or did not disclose their ethnic-
ity. While the majority of White participants were born in
the United States (98%), 2% were immigrants born in
Sub-Saharan Africa (Angola) or Australia. Among the
Black population, 5% were immigrants born in Germany,
Africa (Ghana), Jamaica and the U.S. Virgin Islands. All
others were African-American (95%). Twenty-eight per-
cent of participants were male and 72% were female. The
majority of participants had some level of post-secondary
education (92%), had access to healthcare (94% had
health insurance coverage), and 51% had a yearly house-
hold income greater than US$55,000. The majority of
Black participants were recruited from Hampton, VA
(76% vs. 24%, p = 0.0001) while the majority of White
participants were from Pittsburgh, PA (94% vs. 6%, p <
0.0001). We observed no differences in gender, education
level, access to health care, income, sexual activity or reli-
gion between Black and White participants. However,
74% of the Black participants were between the ages of 18
and 35 years and were statistically significantly younger
than the White participants (22%, p < 0.0001). The
majority of Blacks were single compared with Whites
(75% vs. 25%, p < 0.0001), while the majority of Whites
were married compared with Blacks (58% vs. 15%, p =
0.006). In addition, the majority of Whites (64%) were
parents compared with 33% of Black participants (p =
0.005). The average number of children for each parent
was significantly higher for Blacks compared with Whites
(3 vs. 2 children per parent, p = 0.0001).
HPV knowledge
All study participants were asked to disclose whether or
not they had heard of the human papillomavirus and then
asked to complete 10 additional questions that served to
evaluate the level of HPV knowledge. The proportion of
participants that provided answers to these questions were
calculated after adjusting for potential confounders and
summarized in Table 2. Overall, a large proportion of par-
ticipants had heard of the human papillomavirus (overall
study population: 93.6%; Pittsburgh: 95%, and Hamp-
ton: 90%). Blacks were slightly less aware of HPV than
Whites, however the proportions were not statistically sig-
nificantly different from each other (Blacks 89% vs.
Whites 97% – Table 2). For the 10 questions that assessed
HPV knowledge, in general, Blacks were less knowledgea-
ble than Whites (Table 2).
Overall, 74% of the study population knew that HPV was
sexually transmitted. Although Black participants were
less aware of this information (64%), compared with 81%
of White participants, this difference was only marginally
statistically significant (p = 0.104). Statistical significant
differences were observed between Blacks and Whites for
three specific questions. Only 64% of Black participants
knew that HPV infection was relatively common com-
pared with 88% of White participants (p = 0.013). Simi-
larly, 48% of Black participants knew that there was no
cure for HPV infection compared with 68% of Whites (p
= 0.044). Furthermore, although a large proportion of
participants knew that HPV caused cervical cancer (84%),
Whites were more informed than Blacks (91% vs. 73%, p
= 0.044).Infectious Agents and Cancer 2009, 4(Suppl 1):S10 http://www.infectagentscancer.com/content/4/S1/S10
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For the majority of questions (8/10), the proportion of
Black participants that answered correctly was less 70%
(range: 19.5%–69.2). In contrast, for 5/10 questions, the
proportion of White participants that knew the correct
answers was less than 70% (range: 16.5%–68.4%). There
were four questions that both Black and White partici-
pants answered poorly. Only 37% of Blacks and 52% of
White participants knew that HPV caused genital warts;
20% of Blacks and 17% of Whites knew that genital warts
were not caused by the same HPV type that caused cervical
cancer. Furthermore, when asked: "Who can become
infected with HPV?" only 54% of African-Americans and
65% of Whites knew that both men and women could be
infected. Most importantly, only 69% of African-Ameri-
cans and 66% of Whites were aware that the incidence of
HPV in women is highest among women in their 20 s and
30 s.
Figure 1A shows cumulatively the number of respondents
who provided correct answers to the 10 HPV knowledge-
related questions. Among the participants who provided
correct answers, the majority were successful in answering
at least 7 of the 10 questions. Figure 2 shows the distribu-
tion of correct answers stratified by race and recruitment
site. After adjusting for age, education, income, parental
status and marital status, the overall mean number of cor-
rect answers for the Hampton participants was higher
compared with participants from Pittsburgh (adjusted
mean: 6.7 vs. 6.0). However, this difference was not statis-
tically significant (p = 0.890). Within each recruitment
site (Figure 2A,B), there was no difference between Blacks
and Whites from Hampton (adjusted mean: 6.6 vs. 7.3, p
= 0.707), however, in Pittsburgh, the mean number of
correct answers for Blacks was lower than Whites
(adjusted mean: 4.5 vs. 6.3, p = 0.032).
Table 1: Description of the studied populations according to race
All respondents N (%) Blacks N (%) Whites N (%) Other N (%) p-value*
202 (100) 89 (44.5) 109 (54.5) 2 (1.0)
Location
Hampton, VA 76 (37.6) 68 (76.4) 7 (6.4) 1 (50.0) 0.0001
Pittsburgh, PA 126 (62.4) 21 (23.6) 102 (93.6) 1 (50.0) <0.0001
Age
18–35 90 (45) 65 (73.9) 24 (22.4) 1 (50.0) <0.0001
36–55 63 (32) 20 (22.7) 42 (39.3) -
56+ 45 (23) 3 (3.4) 41 (38.3) 1 (50.0)
Gender
Female 143 (72.2) 61 (69.3) 80 (74.8) 1 (50.0)
Male 55 (27.8) 27 (30.7) 27 (25.2) 1 (50.0)
Parent
Yes 99 (49.0) 28 (32.6) 70 (64.2) 1 (50.0) 0.005
Children (average no, range) 2, 1–5 3, 1–5 2, 1–4 3 0.0001
Education level
High school or less 16 (8) 9 (10.2) 7 (6.4) -
Post-secondary education 184 (92) 79 (89.8) 102 (93.6) 2 (100.0)
Annual household income
Less than $35,000 57 (31.5) 32 (39.0) 23 (24.0) 1 (50.0)
$25,000–$55,000 32 (17.7) 15 (18.3) 17 (17.7) -
Greater than $55,000 92 (50.8) 35 (42.7) 56 (58.3) 1 (50.0)
Health Insurance
No 12 (6.0) 8 (9.0) 3 (2.8) 1 (50.0)
Yes 189 (94.0) 81 (91.0) 106 (97.2) 1 (50.0)
Religion
Christian 150 (77.3) 67 (79.8) 82 (75.9) 1 (50.0)
Other 28 (14.4) 15 (17.9) 12 (11.1) 1 (50.0)
None 16 (8.3) 2 (2.3) 14 (13.0) -
Marital status
Single 96 (47.8) 67 (75.3) 27 (24.8) 1 (50.0) <0.0001
Married 77 (38.3) 13 (14.6) 63 (57.8) 1 (50.0) 0.006
Other 28 (13.9) 9 (10.1) 19 (17.4) -
Sexually active
No 66 (33.3) 26 (30.2) 37 (33.9)
Yes 131 (66.2) 60 (69.8) 71 (65.1)
*p-value shown only when there is a statistically significant difference between Blacks vs. Whites; Race was not defined for 2 participantsInfectious Agents and Cancer 2009, 4(Suppl 1):S10 http://www.infectagentscancer.com/content/4/S1/S10
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Knowledge and perception of the HPV vaccine
Five questions were posed for the knowledge assessment
of the HPV vaccine, summarized in Table 3. Similarly to
the HPV knowledge assessment, proportions of partici-
pants that provided the correct answers were calculated
after adjusting for potential confounders. For four of the
five questions, a lower proportion of Blacks answered the
HPV vaccine knowledge questions correctly compared
with Whites. When participants were asked whether they
had heard of the HPV vaccine, 87% answered affirma-
tively (Pittsburgh: 92% and Hampton: 74%, p = 0.029)
and a higher proportion of Whites were aware of the vac-
cine compared with Blacks (93% vs. 76%, p = 0.031).
However, despite this heightened awareness, only 18% of
the overall study population knew that the current FDA-
approved vaccine protected against genital warts and most
cervical cancer (20% of Blacks and 16% of Whites – Table
3).
Although marginally statistically significant, a lower pro-
portion of Blacks were aware that only females were eligi-
ble for the HPV vaccine (64%) at this time compared with
81% of White participants (p = 0.106). In contrast, statis-
tically significant differences were observed for other
questions. Forty-nine percent of Blacks compared with
81% of Whites knew that the HPV vaccine was approved
for participants who have never been infected with HPV
(p = 0.004). Furthermore, 63% of Blacks and 90% of
Whites knew that 9–26 years was the correct age group for
which the HPV vaccine was recommended (p = 0.012).
Among the participants that provided correct answers to
the HPV vaccine knowledge questions, the majority of
participants were able to answer four out of the five ques-
tions correctly (Figure 1B). Overall, the mean number of
correct answers were the same for Pittsburgh and Hamp-
ton participants (adjusted mean: 3.2 vs. 3.1, p = 0.883).
Regardless of recruitment site, White participants
appeared to be more knowledgeable than Black partici-
pants, since the mean number of correct answers was
higher in White participants recruited from both Pitts-
burgh (3.4 vs. 2.7, p = 0.001) and Hampton (3.6 vs. 3.0,
p = 0.887) (Figure 3A,B).
Six questions were posed in order to evaluate the study
participant's perception of the HPV vaccine (Figure 4).
When participants were asked whether a well-informed
child should be able to request vaccination at sexual
health clinics without parental consent, a high proportion
of participants agreed but a nearly equal number of partic-
ipants also disagreed. The majority of participants disa-
greed that HPV vaccination may encourage risky sexual
behavior in adolescents. Overall, the majority of partici-
pants agreed that it was necessary to discuss issues of sex-
uality before recommending the HPV vaccine to
adolescents and that reassurance on the efficacy and safety
of the vaccine is still needed. Although more participants
agreed that the HPV vaccine should be given to boys as
well as girls, there was no consensus because a nearly
equal number of participants disagreed and a proportion
of participants were unsure.
Table 2: Assessment of HPV knowledge: adjusted proportions of the correct answers by race
Blacks*
(95% CI)
Whites*
(95% CI)
p-value
Have you heard of the Human Papillomavirus (HPV)? Answer = Yes 89.3% (75.5%–95.8%) 96.9% (90.6%–99.0%)
HPV is not sexually transmitted
Answer = False
63.9% (47.7%–77.4%) 81.0% (69.6%–88.8%)
HPV infection is relatively uncommon
Answer = False
63.8% (47.6%–77.4%) 87.7% (78.4%–93.3%) 0.013
HPV causes cervical cancer
Answer = True
73.2% (57.2%–84.8%) 90.7% (81.6%–95.5%) 0.044
Who can become infected with HPV?
Answer = Both women and men
54.4% (38.7%–69.2%) 65.1% (51.5%–76.6%)
Both men and women can have cervical cancer
Answer = False
83.6% (67.9%–92.5%) 95.8% (87.4%–98.7%)
The incidence of HPV in women is highest among women in their 20's and 30's
Answer = True
69.2% (53.9%–81.2%) 65.9% (52.2%–77.4%)
Most people with genital HPV infections are symptomatic
Answer = False
41.5% (26.5%–58.3%) 73.6% (60.5%–83.5%) 0.014
HPV causes genital warts
Answer = True
37.3% (24.1%–52.7%) 51.7% (38.6%–64.5%)
Genital warts are caused by the same HPV types that cause cervical cancer
Answer = False
19.5% (10.3%–33.8%) 16.5% (8.7%–28.9%)
There is a cure for HPV infection
Answer = False
47.6% (31.2%–64.6%) 68.4% (54.3%–79.8%)
*Proportions adjusted for location, age, education, income, parental status and marital status; p-value shown only when there is a statistically 
significant difference between Blacks and Whites.Infectious Agents and Cancer 2009, 4(Suppl 1):S10 http://www.infectagentscancer.com/content/4/S1/S10
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Discussion
A number of US studies have been conducted to address
knowledge and attitudes related to HPV and the HPV vac-
cine. However, few are population-based. Many of these
have been based on focus groups [9-11] or are studies that
primarily involved a distinct racial and/or ethnic group
[12,13]. A recent study of females from the US general
population has been published; this study, however, did
not include comparisons of knowledge and attitudes
between ethnic or racial groups and geographic locations
[14]. We have, for the first time, reported the assessment
of HPV and HPV vaccine knowledge and perception in a
sample of the general population (both males and
females) in Pittsburgh, Pennsylvania and Hampton, Vir-
ginia, USA. We have compared our findings by race as well
as by geographic location. Overall, our findings show that
in this study population, Blacks are less knowledgeable
about HPV compared with Whites. The majority of partic-
ipants were unaware of important information about
HPV infection, in general. Although a substantial propor-
tion of the study population knew that HPV was sexually
transmitted (78%), only 64% of Black participants were
knowledgeable compared with 81% of the White partici-
pants. Furthermore, a smaller proportion of Blacks knew
that both males and females could be infected with HPV
(Blacks 54% vs. Whites 65%); roughly 2/3 of those inter-
viewed knew that the incidence of HPV infection is high-
est among women in their 20 s and 30 s (Blacks 69% vs.
Whites 65%). These data suggest that simple education
might serve not only to increase awareness about the risks
associated with HPV infection, but may promote changes
in behavior that might lead to risk reduction of HPV infec-
tion.
Two large population-based surveys involving random
samples of 1,006 participants in the US [14] and of US
Distribution of the predicted number of correct answers to  the 10 questions which assessed HPV knowledge, stratified  by ethnicity and recruitment location and adjusted for age,  education, income, parental status and marital status Figure 2
Distribution of the predicted number of correct answers to 
the 10 questions which assessed HPV knowledge, stratified 
by ethnicity and recruitment location and adjusted for age, 
education, income, parental status and marital status. The 
adjusted mean for each stratum is denoted by dashed lines.
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women, ages 18–75 years [15], reported that about 40–
41% of participants knew that HPV caused cervical cancer.
In our study population, the majority of participants
(81%) were aware of this information, and a smaller pro-
portion of Black participants were knowledgeable com-
pared with Whites (73% vs. 91%). One possible
explanation for the differences in reported findings
between other studies and ours is that the majority of par-
ticipants in our study consisted of participants with some
post-secondary education. Nevertheless, since HPV is the
etiologic agent for cervical and most other anogenital can-
cers [16-18] and has been implicated in oropharyngeal
cancers [1,2], information related to HPV infection is cru-
cial to an individual's understanding of their risk for infec-
tion and development of these serious diseases.
We compared the distribution of correct answers to the
HPV knowledge questions between geographic locations
and observed that overall the mean number of correct
answers was higher for Hampton participants compared
Participants' responses to questions that evaluated their perception of the HPV vaccine Figure 4
Participants' responses to questions that evaluated their perception of the HPV vaccine.
0 1 02 03 04 05 06 07 08 09 0 1 0 0
It is necessary to discuss issues of sexuality before recommending
the HPV vaccine to adolescents
Vaccination against HPV may encourage risky sexual behavior in
adolescents
A well-informed child should be able to request vaccination at
sexual health clinics without parental consent
Reassurance on the efficacy of the HPV vaccine is still needed
Reassurance of the safety of the HPV vaccine is still needed
The HPV vaccine should be given to boys as well as girls
Percent of respondents (%)
Agree
Disagree
Not Sure
Table 3: Knowledge assessment of the HPV vaccine: adjusted proportions of the correct answers by race
Blacks*
(95% CI)
Whites*
(95% CI)
p-value
Have you heard about the HPV vaccine?
Answer = Yes
76.4% (60.1%–87.4%) 93.3% (84.9%–97.2%) 0.031
The HPV vaccine is approved for individuals who have never been infected with HPV
Answer = True
48.8% (33.8%–64.0%) 81.2% (69.9%–88.9) 0.004
Who is eligible for the HPV vaccine?
Answer = Females
63.7% (47.8%–77.1%) 81.3% (69.2%–89.3%)
For which age group is the HPV vaccine recommended?
Answer = 9–26
63.2% (46.6%–77.2%) 89.5% (78.5%–95.2%) 0.012
The current FDA approved HPV vaccine protects against genital warts and most cervical 
cancer
Answer = True
20.0% (10.0%–36.1%) 16.1% (8.1%–29.3%)
Once vaccinated women no longer have to be screened (annual pap smears) for cervical 
cancer
Answer = False
78.9% (63.8%–88.8%) 91.7% (82.7%–96.3%)
*Proportions adjusted for location, age, education, income, parental status and marital status; p-value shown only when there is a statistically 
significant difference between Blacks and Whites.Infectious Agents and Cancer 2009, 4(Suppl 1):S10 http://www.infectagentscancer.com/content/4/S1/S10
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with Pittsburgh participants, although this difference was
not statistically significant. When we compared the Black
and White participants from Pittsburgh, we observed that
Blacks had a smaller mean number of correct answers
compared with Whites, while there was no difference
between races for Hampton participants. Overall, these
findings suggest a need for increased educational pro-
grams on HPV and the clinical manifestations of HPV
infections for the general popualtion residing in the Pitts-
bugrh area as well as for Black participants living in both
geographic areas.
We have reported that 87% of participants had heard of
the HPV vaccine. However, despite this high proportion
of participants, the majority did not know about the pro-
tective impact. Only 18% of participants knew that the
HPV vaccine protected against most cervical cancer and
genital warts. This suggests that the general population
may not be equipped with the necessary information to
make an informed decision about HPV vaccination. We
also observed that Blacks were less well informed about
the HPV vaccine compared with Whites. However, the dif-
ferences were statistically significant only for the Pitts-
burgh population, suggesting a need for targeted
education programs on the HPV vaccine in this group.
Conclusion
These data suggest that although the general population
might be aware of HPV and the HPV vaccine, knowledge
of the benefits from the HPV vaccination may not be
apparent. There were also differences in the level of
knowledge based on ethnicity and geographic location.
The development of educational interventions is neces-
sary to ensure that the general public is able to make an
informed decision regarding HPV vaccination.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CR, ET, RPE, SMG and DEH conceived the study and par-
ticipated in the study design. CR developed the survey
instrument, performed the data entry and analysis. CAS
and CB were responsible for overseeing the data collection
at Hampton, VA. KH, EJ, CM and AS participated in the
participant recruitment and data collection at Hampton,
VA; JJ, AA, NET and LR participated in participant recruit-
ment and data collection in Pittsburgh, PA. All authors
read and approved the final manuscript.
Acknowledgements
This study was supported in part by grant number: R13CA130596A to CR 
and P20CA132385-01 to ET. This work was also supported in part by funds 
from the University of Pittsburgh, Graduate School of Public Health, Dean's 
office and the University of Pittsburgh Cancer Institute. This publication 
was also made possible by Grant Number KL2 RR024154-03 from the 
National Center for Research Resources (NCRR) [19], a component of the 
National Institutes of Health (NIH), and NIH Roadmap for Medical 
Research [20]. Its contents are solely the responsibility of the authors and 
do not necessarily represent the official view of NCRR or NIH.
This article has been published as part of Infectious Agents and Cancer. Vol-
ume 4 Supplement 1, 2009: Second Annual International African-Caribbean 
Cancer Consortium Conference. The full contents of the supplement are 
available online at http://www.infectagentscancer.com/4/supplements/4/S1.
References
1. Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F, et
al.: 11q13 amplification status and human papillomavirus in
Distribution of the predicted number of number of correct  answers to the five questions which assessed knowledge of  the HPV vaccine, stratified by ethnicity and recruitment loca- tion and adjusted for age, education, income, parental status  and marital status Figure 3
Distribution of the predicted number of number of correct 
answers to the five questions which assessed knowledge of 
the HPV vaccine, stratified by ethnicity and recruitment loca-
tion and adjusted for age, education, income, parental status 
and marital status. The adjusted mean for the number of cor-
rect answers in each stratum is denoted by dashed lines.
1
2
3
4
A
d
j
u
s
t
e
d
 
m
e
a
n
s
Whites Blacks
Hampton
1
.
5
2
2
.
5
3
3
.
5
4
A
d
j
u
s
t
e
d
 
m
e
a
n
s
Whites Blacks
Pittsburgh
A
BPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Infectious Agents and Cancer 2009, 4(Suppl 1):S10 http://www.infectagentscancer.com/content/4/S1/S10
Page 9 of 9
(page number not for citation purposes)
relation to p16 expression defines two distinct etiologies of
head and neck tumours.  Br J Cancer 2006, 95:1432-1438.
2. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L,
et al.: Evidence for a causal association between human papil-
lomavirus and a subset of head and neck cancers.  J Natl Cancer
Inst 2000, 92:709-720.
3. FDA Licenses New Vaccine for Prevention of Cervical Can-
cer and Other Diseases in Females Caused by Human Papil-
lomavirus, Food & Drug Administration   [http://www.fda.gov/
bbs/topics/NEWS/2006/NEW01385.html]
4. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger
ER:  Quadrivalent Human Papillomavirus Vaccine: Recom-
mendations of the Advisory Committee on Immunization
Practices (ACIP).  MMWR Recomm Rep 2007, 56:1-24.
5. Lowy DR, Howley PM: Papillomaviruses.  In Fields Virology Edited
by: Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins;
2001:2231-2240. 
6. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Ham-
mouda D, et al.: Against which human papillomavirus types
shall we vaccinate and screen? The international perspec-
tive.  Int J Cancer 2004, 111:278-285.
7. VFC: The ACIP-VFC Vaccine Resolutions, Centers for Dis-
ease Control and Prevention   [http://www.cdc.gov/vaccines/pro
grams/vfc/acip-vfc-resolutions.htm]
8. HPV vaccine, National Conference of State Legislatures
(NCSL)   [http://www.ncsl.org/programs/health/HPVvaccine.htm]
9. Anhang R, Wright TC Jr, Smock L, Goldie SJ: Women's desired
information about human papillomavirus.  Cancer 2004,
100:315-320.
10. Vanslyke JG, Baum J, Plaza V, Otero M, Wheeler C, Helitzer DL: HPV
and cervical cancer testing and prevention: knowledge,
beliefs, and attitudes among Hispanic women.  Qual Health Res
2008, 18:584-596.
11. Goldsmith MR, Bankhead CR, Kehoe ST, Marsh G, Austoker J: Infor-
mation and cervical screening: a qualitative study of
women's awareness, understanding and information needs
about HPV.  J Med Screen 2007, 14:29-33.
12. Gerend MA, Magloire ZF: Awareness, Knowledge, and Beliefs
about Human Papillomavirus in a Racially Diverse Sample of
Young Adults.  Journal of Adolescent Health 2008, 42:237-242.
13. D'Urso J, Thompson-Robinson M, Chandler S: HPV knowledge
and behaviors of black college students at a historically black
university.  J Am Coll Health 2007, 56:159-163.
14. Tiro JA, Meissner HI, Kobrin S, Chollette V: What Do Women in
the U.S. Know about Human Papillomavirus and Cervical
Cancer?  Cancer Epidemiol Biomarkers Prev 2007, 16:288-294.
15. National Survey of Public Knowledge of HPV, the Human
Papillomavirus, The Kaiser Family Foundation   [http://
www.kff.org/womenshealth/upload/The-HPV-Test-Coming-Soon-to-
a-Doctor-s-Office-Near-You-Is-It-Better-than-the-Pap-Smear-for-
Detecting-Cervical-Cancer-Chart-Pack.pdf]
16. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV: The causal
relation between human papillomavirus and cervical cancer.
Journal of Clinical Pathology 2002, 55:244-265.
17. Bosch FX, de Sanjose S: Chapter 1: Human papillomavirus and
cervical cancer – burden and assessment of causality.  Journal
of the National Cancer Institute Monographs 2003:3-13.
18. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wur-
scher MA, et al.: Human papillomavirus, smoking, and sexual
practices in the etiology of anal cancer.  Cancer 2004,
101:270-280.
19. National Institutes of Health, National Institutes of Health,
National Center for Research Resources   [ h t t p : / /
www.ncrr.nih.gov/]
20. NIH Roadmap for Medical Research, NIH Roadmap for Med-
ical Research, Re-engineering the Clinical Research Enter-
prise   [http://nihroadmap.nih.gov/clinicalresearch/overview-
translational.asp]